medmix AG (MEDX) AI Stock Analysis

• Market Cap: CHF389.93M
• Dividend Yield: 4.54%
• Average Volume (3M): 115.75K
• Price to Earnings (P/E): 60.2
• Beta (1Y): 1.14
• Revenue Growth: -2.42%
• EPS Growth: -222.68%
• Country: CH
• Employees: 2,684
• Sector: Healthcare
• Sector Strength: 45
• Industry: Industrial - Machinery
• EPS (TTM): 0.33
• Shares Outstanding: 41,262,370
• 10 Day Avg. Volume: 183,978
• 30 Day Avg. Volume: 115,752
• PEG Ratio: 0.02
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.74
• P/FCF Ratio: 9.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.69
• Revenue Forecast (FY): CHF475.81M

• Rating: 56 Neutral
• Price Target: CHF12.00 ▲(6.76% Upside)
• Action: Reiterated Date: 11/26/25
• Date: Action: Reiterated 11/26/25

The overall stock score is primarily influenced by the company's mixed financial performance, with operational challenges and increased leverage being significant concerns. Technical analysis indicates a bearish trend, while valuation is affected by a negative P/E ratio, although the high dividend yield offers some compensation.

Positive Factors

Recurring consumables / installed base

medmix’s business model includes recurring consumable sales tied to an installed base (mixing tips, nozzles). This creates steady, repeatable revenue streams and higher customer lifetime value, insulating top-line volatility and supporting durable cash flows as installed systems continue to drive consumable demand.

Operating cash flow resilience

Improved operating cash flow and a strong operating cash flow to net income ratio indicate medmix converts earnings to cash efficiently. Durable OCF supports reinvestment in R&D and capex, funds working capital for program ramps, and provides flexibility to manage leverage without relying solely on external financing.

Stable gross profit margin

A roughly 33% gross margin over time indicates sustainable product-level economics and pricing power on core hardware and consumables. Consistent gross margins provide a buffer against cost inflation and underpin long-term margin recovery if operating expenses are optimized and volumes grow.

Negative Factors

Rising leverage

Increasing leverage reduces financial flexibility and raises interest expense sensitivity during rate cycles. Higher debt relative to equity constrains strategic options (M&A, capex) and increases default and covenant risk, making multi-quarter recovery plans harder to execute without improving cash generation or deleveraging.

Weak revenue & EPS trends

Negative revenue growth and severely contracted EPS indicate demand and profitability pressures. Prolonged top-line weakness limits scale benefits, reduces ability to invest in programs, and can weaken long-term customer wins in healthcare and industrial channels where multi-year contracts and consistent delivery are critical.

Volatile net margins and declining EBIT

Volatile net margins and declining EBIT point to structural operational challenges in converting gross profit to net earnings. Persistent margin volatility erodes retained earnings, limits reinvestment capacity, and may require restructuring or pricing adjustments to restore sustainable profitability over the medium term.

medmix AG Business Overview & Revenue Model

Company Description

Medmix AG designs, develops, manufactures, and delivers high-precision devices and services for the mixing, application, and injection of liquids in a range of viscosities for the healthcare, consumer, and industrial end markets worldwide. It operates through five segments: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers mixing tips, dispensers, needles, accessories, and service solutions for various applications, such as prosthetics, restorations, anesthetics, and aesthetics. The Drug Delivery segment offers drug delivery devices that are used to inject fertility drugs and growth hormones; and to treat niche diabetes indications, osteoporosis, and rare diseases. The Surgery segment provides mixing and delivery devices which are used to inject bone cement, and to apply hemostatic sealants for internal and external wound treatment during surgical procedures. The Industry segment produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in the construction, transportation, electronics, infrastructure, and general industrial sectors. The Beauty segment offers micro brushes, mascara, lip gloss and concealers. The company offers its products under the Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka brands. The company was founded in 1922 and is based in Zug, Switzerland.

How the Company Makes Money

medmix AG generates revenue primarily through the sale of its advanced delivery systems and products across its various sectors. The company's key revenue streams include the manufacturing and distribution of injection systems for pharmaceuticals, medical devices, and consumer goods. Additionally, medmix benefits from long-term partnerships with major pharmaceutical and biotech companies, which often involve collaboration on specialized projects and co-development of innovative delivery solutions. The company also focuses on expanding its market reach through strategic acquisitions and investments in research and development, which contribute to its overall earnings by enhancing its product offerings and improving operational efficiencies.

medmix AG Financial Statement Overview

Summary

medmix AG faces mixed financial health. While cash flow generation shows some resilience, the income statement highlights profitability challenges, and the balance sheet indicates increasing leverage. The company needs to bolster revenue growth and manage liabilities to improve its financial standing.

Income Statement

The company shows a stable gross profit margin of approximately 33% over the years, but the net profit margin has been volatile, recently turning negative in the latest period. Though revenue has shown minimal fluctuation, the overall growth trajectory is weak. EBIT and EBITDA margins suggest operational challenges, with declining EBIT over recent periods.

Balance Sheet

The company's debt-to-equity ratio has increased over time, indicating higher leverage, while the equity ratio has slightly decreased. Return on equity has diminished, reflecting reduced profitability. The balance sheet reveals potential risks from increased liabilities relative to equity.

Cash Flow

The company has improved its cash flow operations, evident from positive operating cash flow growth. However, free cash flow growth has been inconsistent, although it has turned positive recently. The operating cash flow to net income ratio is strong, indicating efficient cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	468.10M	483.90M	486.60M	477.10M	457.30M	351.30M
Gross Profit	161.60M	159.70M	157.70M	175.40M	181.20M	121.10M
EBITDA	65.10M	67.60M	68.40M	68.30M	110.60M	60.90M
Net Income	-5.80M	-7.40M	300.00K	11.60M	44.00M	9.60M
Balance Sheet
Total Assets	952.60M	954.20M	1.01B	1.11B	974.40M	789.90M
Cash, Cash Equivalents and Short-Term Investments	108.40M	96.20M	130.60M	316.80M	210.00M	46.20M
Total Debt	320.50M	323.40M	349.70M	473.50M	320.90M	332.30M
Total Liabilities	522.10M	507.50M	532.40M	601.10M	440.50M	456.50M
Stockholders Equity	424.00M	436.40M	465.40M	504.80M	533.90M	333.40M
Cash Flow
Free Cash Flow	51.70M	38.10M	3.20M	9.00M	55.40M	7.50M
Operating Cash Flow	88.40M	86.60M	56.10M	47.60M	87.30M	50.60M
Investing Cash Flow	-49.40M	-51.50M	-80.60M	-57.00M	-3.30M	4.40M
Financing Cash Flow	-75.10M	-48.60M	-153.80M	116.10M	111.60M	-42.90M

medmix AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MEDX, the sentiment is Negative. The current price of 11.24 is below the 20-day moving average (MA) of 11.38, below the 50-day MA of 11.41, and above the 200-day MA of 10.66, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 20.71 is Positive, neither overbought nor oversold. The STOCH value of 22.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MEDX.

medmix AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MIKN	71 Outperform	CHF283.29M	9.14	14.20%	2.43%	-1.94%	6.63%
MEDX	56 Neutral	CHF389.93M	60.19	―	4.54%	-2.42%	-222.68%
STGN	54 Neutral	CHF185.92M	-49.51	―	3.45%	-1.46%	-115.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KOMN	49 Neutral	CHF348.15M	-33.68	―	―	-13.64%	-281.19%
FTON	49 Neutral	CHF153.97M	-19.17	-9.74%	―	-15.70%	-670.93%
RIEN	46 Neutral	CHF412.17M	-2.48	―	7.53%	-28.40%	-117.97%